Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03517488
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:38:53.814241+00:00
Published At
2022-12-01T00:00:00+00:00
Record Updated At
2022-12-01
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Melanoma", "Breast Carcinoma", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Non-small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Endometrial Carcinoma", "Mesothelioma", "Neuroendocrine Carcinoma", "Cervical Cancer", "Small Cell Lung Carcinoma", "Squamous Cell Carcinoma of the Anus", "Castration-Resistant Prostate Carcinoma", "Nasopharyngeal Carcinoma", "Cholangiocarcinoma", "Basal Cell Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Thymoma", "Thymic Carcinoma", "Squamous Cell Carcinoma of the Penis", "Vulvar Carcinoma", "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy", "Malignant Adnexal Neoplasms", "Non-squamous Cell Salivary Gland Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-12-01"
protocolSection.identificationModule.nctId
"NCT03517488"
protocolSection.identificationModule.officialTitle
"A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb\u00ae20717 in Subjects With Selected Advanced Solid Tumors"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Melanoma (protocolSection.conditionsModule.conditions)
  • Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma of the Head and Neck (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Colorectal Carcinoma (protocolSection.conditionsModule.conditions)
  • Non-small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Gastric or Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Endometrial Carcinoma (protocolSection.conditionsModule.conditions)
  • Mesothelioma (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Carcinoma (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma of the Anus (protocolSection.conditionsModule.conditions)
  • Castration-Resistant Prostate Carcinoma (protocolSection.conditionsModule.conditions)
  • Nasopharyngeal Carcinoma (protocolSection.conditionsModule.conditions)
  • Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
  • Basal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Ovarian Carcinoma (protocolSection.conditionsModule.conditions)
  • Fallopian Tube Carcinoma (protocolSection.conditionsModule.conditions)
  • Thymoma (protocolSection.conditionsModule.conditions)
  • Thymic Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma of the Penis (protocolSection.conditionsModule.conditions)
  • Vulvar Carcinoma (protocolSection.conditionsModule.conditions)
  • Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy (protocolSection.conditionsModule.conditions)
  • Malignant Adnexal Neoplasms (protocolSection.conditionsModule.conditions)
  • Non-squamous Cell Salivary Gland Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.